Study: Blood-based 'liquid biopsy' cancer testing works

A study that included genetic information from 15,000 patients across 50 tumor types confirmed the accuracy of the tests for diagnostic and tumor-tracking purposes. 

By Nicole Gray • June 8, 2016

Vermont becomes first state with drug pricing justification law

Gov. Peter Shumlin has implemented a law requiring state officials to identify drugs that rose by 50% or more in the last five years. 

By Nicole Gray • June 8, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Genentech/OSI fined $67 million for skewing cancer-drug survival data

According to the Department of Justice (DOJ),  between 2006 and 2011, the two companies misled physicians who treated patients with non-small cell lung cancer (NSCLC) with Tarceva (erlotinib). 

By Nicole Gray • June 8, 2016

Senators request pricing info from opioid-overdose drugmakers

Senators Susan Collins (R-ME) and Claire McCaskill (D-MO) have sent letters to five companies regarding naloxone price hikes. 

By Nicole Gray • June 8, 2016

Study: Cancer drugs most expensive in US, least accessible in China, India

In a study that evaluated cost of cancer drugs as a percentage of per capita GDP, Australia had the most affordable drugs. 

By Nicole Gray • June 6, 2016

AstraZeneca continues to shed rights to gout drug

Germany-based Grünenthal will pay up to $230 million for European and Latin American rights to Zurampic, a month after AstraZeneca sold U.S. rights to Ironwood. 

By Nicole Gray • June 3, 2016

Novartis cancer drug wins expanded indication in Europe

Although Afinitor brought in $1.6 billion last year, sales have dipped as the drug faces stiffer competition.

By Nicole Gray • June 2, 2016

Global cancer drug spending rises, set to surpass $150 billion by 2020

A wave of new drugs entering the market over the past five years has helped drive spending higher, according to a new report from IMS Health.

By Ned Pagliarulo • June 2, 2016

Kite Pharma rides CAR-T momentum into ASCO

BioPharma Dive spoke to the immuno-oncology biotech to find out how its lead cell therapy is progressing as it aims for a 2017 launch.

By Nicole Gray • June 2, 2016

AstraZeneca discontinues 'Take it From a Fish' ad campaign

The campaign had won a prize at the Lions Health festival last year and featured two dead fish joking about triglycerides. 

By Nicole Gray • June 1, 2016

Next-generation eczema drugs on pace for 2017 launch

Anacor Pharma has already submitted its drug, crisaborole, to the FDA for approval, while Regeneron and Sanofi aim to file later this year for their drug dupilumab. 

By Nicole Gray • May 31, 2016

Transforming the Healthcare Model

Digital platforms are substantially improving the quality of medical information healthcare professionals receive, helping them enhance the patient experience.

By Roni Robbins • May 31, 2016

Bristol-Myers attacks cost-effectiveness study of cancer drug

A recent assessment by the Institute of Clinical and Economic Review recommended steep discounts for several new multiple myeloma drugs, including Bristol-Myers' Empliciti.

By Ned Pagliarulo • May 26, 2016

While advancing cancer pipeline, Halozyme builds up through pharma collaborations

BioPharma Dive spoke with Helen Torley, CEO of Halozyme, about breaking down treatment barriers and easing the burden of biologic drug delivery.   

By Nicole Gray • May 25, 2016

New ad for Bristol's Opdivo highlights testing advantage over Keytruda

Competition in immuno-oncology looks set to heat up as Roche's Tecentriq recently won FDA approval, albeit for a different indication initially.

By Nicole Gray • May 24, 2016

Eyeing US market, Samsung applies for approval of biosimilar Remicade

South Korean rival Celltrion recently won FDA approval for its own copy of the blockbuster anti-inflammatory drug. 

By Ned Pagliarulo • May 24, 2016

Sanofi diabetes chief to leave company as US business struggles

Competition and a tougher payer environment have led to lower sales from the important diabetes division. 

By Nicole Gray • May 24, 2016

China slashes prices of top-selling cancer, hep B drugs

The price cuts, which are at least 50%, were agreed upon by the central government and drug makers after negotiations. 

By Nicole Gray • May 23, 2016

EMA removes warning from Pfizer smoking cessation drug

A major post-marketing study recently showed use of Chantix did not increase the risk of neuropsychiatric side effects. 

By Ned Pagliarulo • May 23, 2016

Novartis' Entresto gets boost from leading US cardiology groups

The American College of Cardiology, the American Heart Association and the Heart Failure Society of America have jointly updated guidelines giving the drug a class one recommendation for management of heart failure. 

By Nicole Gray • May 23, 2016

As big pharma moves in, biotech Galectin looks to stake claim to NASH market

NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020. 

By Nicole Gray • May 18, 2016

Everyday low price? Walmart teams with McKesson to source generics

The companies say they hope the deal will add both scale and value to their existing distribution agreement. 

By Nicole Gray • May 18, 2016

Orexigen struggles to stay afloat as obesity market stagnates

After slow sales of Contrave last year and the exit of its co-marketing partner Takeda, Orexigen is predicting "zero-to-limited" growth for its obesity drug. 

By Nicole Gray • May 18, 2016

Novartis debates how to crack sales code for CAR-T therapy

No therapies have been approved yet, but their expected high cost and complex distribution process could require alternative marketing frameworks.

By Nicole Gray • May 17, 2016

After criticism, Valeant details plans for hospital discounts on heart drugs

Although the company had promised discounts on Nitropress and Isuprel earlier this year, a Senate committee investigation found few hospitals had actually received any relief. 

By Ned Pagliarulo • May 16, 2016